OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate
Aaron Richterman, Amy J. Behrman, Patrick J. Brennan, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e319-e326
Open Access | Times Cited: 22
Aaron Richterman, Amy J. Behrman, Patrick J. Brennan, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e319-e326
Open Access | Times Cited: 22
Showing 22 citing articles:
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 189
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 189
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 178
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 178
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 50
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 50
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Shanti Pather, Alexander Muik, Ruben Rizzi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 650-661
Open Access | Times Cited: 16
Shanti Pather, Alexander Muik, Ruben Rizzi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 650-661
Open Access | Times Cited: 16
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 15
Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e076892-e076892
Open Access | Times Cited: 15
COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
Yousra Kherabi, Odile Launay, Liêm Binh Luong Nguyen
Viruses (2022) Vol. 14, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 18
Yousra Kherabi, Odile Launay, Liêm Binh Luong Nguyen
Viruses (2022) Vol. 14, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 18
Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort
Ida Laake, Siri N. Skodvin, Kristine Blix, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1924-1933
Open Access | Times Cited: 16
Ida Laake, Siri N. Skodvin, Kristine Blix, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1924-1933
Open Access | Times Cited: 16
Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study
Helena C. Maltezou, Maria N. Gamaletsou, Dimitra‐Maria Koukou, et al.
Vaccine (2022) Vol. 40, Iss. 52, pp. 7660-7666
Open Access | Times Cited: 12
Helena C. Maltezou, Maria N. Gamaletsou, Dimitra‐Maria Koukou, et al.
Vaccine (2022) Vol. 40, Iss. 52, pp. 7660-7666
Open Access | Times Cited: 12
Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis
Kaixin Guo, Peng Ni, Shuailei Chang, et al.
American Journal of Infection Control (2023) Vol. 51, Iss. 9, pp. 1049-1055
Closed Access | Times Cited: 7
Kaixin Guo, Peng Ni, Shuailei Chang, et al.
American Journal of Infection Control (2023) Vol. 51, Iss. 9, pp. 1049-1055
Closed Access | Times Cited: 7
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Susceptibility of healthcare personnel with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) hybrid immunity to XBB lineage reinfection
Karissa Whiting, Rebecca Guest, Venkatraman Seshan, et al.
Infection Control and Hospital Epidemiology (2024) Vol. 45, Iss. 6, pp. 781-784
Closed Access | Times Cited: 1
Karissa Whiting, Rebecca Guest, Venkatraman Seshan, et al.
Infection Control and Hospital Epidemiology (2024) Vol. 45, Iss. 6, pp. 781-784
Closed Access | Times Cited: 1
COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review
Oliver Galgut, Fiona Ashford, Alexandra Deeks, et al.
Vaccine X (2024) Vol. 20, pp. 100546-100546
Open Access | Times Cited: 1
Oliver Galgut, Fiona Ashford, Alexandra Deeks, et al.
Vaccine X (2024) Vol. 20, pp. 100546-100546
Open Access | Times Cited: 1
COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021–2022: a test-negative case–control study
Cátia Brazete, Jessica Brazete, Fabio Alves, et al.
Public Health (2023) Vol. 218, pp. 84-91
Open Access | Times Cited: 3
Cátia Brazete, Jessica Brazete, Fabio Alves, et al.
Public Health (2023) Vol. 218, pp. 84-91
Open Access | Times Cited: 3
Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization
Ji Wang, Yanhao Zhang, Chao Liu, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 10, pp. 4971-4983
Closed Access | Times Cited: 3
Ji Wang, Yanhao Zhang, Chao Liu, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 10, pp. 4971-4983
Closed Access | Times Cited: 3
Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Panke Qu, Julia N. Faraone, John P. Evans, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study
Sabir Meah, Xu Shi, Lars G. Fritsche, et al.
Science Advances (2023) Vol. 9, Iss. 51
Open Access | Times Cited: 2
Sabir Meah, Xu Shi, Lars G. Fritsche, et al.
Science Advances (2023) Vol. 9, Iss. 51
Open Access | Times Cited: 2
Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil
Alexandre R. Marra, João Luiz Miraglia, Daniel Tavares Malheiro, et al.
Antimicrobial Stewardship & Healthcare Epidemiology (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Alexandre R. Marra, João Luiz Miraglia, Daniel Tavares Malheiro, et al.
Antimicrobial Stewardship & Healthcare Epidemiology (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS‐CoV ‐2 Omicron in patients with haematological malignancies: A national prospective cohort study
Lukas Kevličius, Karolis Šablauskas, Kazimieras Maneikis, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 497-506
Open Access | Times Cited: 1
Lukas Kevličius, Karolis Šablauskas, Kazimieras Maneikis, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 497-506
Open Access | Times Cited: 1
SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysis
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study
Sabir Meah, Xu Shi, Lars G. Fritsche, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Sabir Meah, Xu Shi, Lars G. Fritsche, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
